232 related articles for article (PubMed ID: 18419677)
1. Clinical relevance of serum levels of matrix metallopeptidase-2, and tissue inhibitor of metalloproteinase-1 and -2 in patients with malignant melanoma.
Yoshino Y; Kageshita T; Nakajima M; Funakubo M; Ihn H
J Dermatol; 2008 Apr; 35(4):206-14. PubMed ID: 18419677
[TBL] [Abstract][Full Text] [Related]
2. [Expression and significance of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase in non-melanoma skin cancer].
Fu XR; Zhang C; Chen CY; Zhang L; Wang LX; Wang BH; Liu XY; Zhang MZ
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):369-73. PubMed ID: 22883459
[TBL] [Abstract][Full Text] [Related]
3. Expression and serum levels of MMP-2 and MMP-9 during human melanoma progression.
Redondo P; Lloret P; Idoate M; Inoges S
Clin Exp Dermatol; 2005 Sep; 30(5):541-5. PubMed ID: 16045689
[TBL] [Abstract][Full Text] [Related]
4. Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
Airola K; Karonen T; Vaalamo M; Lehti K; Lohi J; Kariniemi AL; Keski-Oja J; Saarialho-Kere UK
Br J Cancer; 1999 May; 80(5-6):733-43. PubMed ID: 10360651
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 is correlated with poor prognostic variables in patients with thymic epithelial tumors.
Sogawa K; Kondo K; Fujino H; Takahashi Y; Miyoshi T; Sakiyama S; Mukai K; Monden Y
Cancer; 2003 Nov; 98(9):1822-9. PubMed ID: 14584061
[TBL] [Abstract][Full Text] [Related]
6. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
8. Concentration of metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in the serum of patients with benign and malignant thyroid tumours treated surgically.
Pasieka Z; Stepien H; Czyz W; Pomorski L; Kuzdak K
Endocr Regul; 2004 Jun; 38(2):57-63. PubMed ID: 15497929
[TBL] [Abstract][Full Text] [Related]
9. Serum matrix metalloproteinase-8 is associated with ulceration and vascular invasion of malignant melanoma.
Vihinen P; Koskivuo I; Syrjänen K; Tervahartiala T; Sorsa T; Pyrhönen S
Melanoma Res; 2008 Aug; 18(4):268-73. PubMed ID: 18626311
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours.
Kolomecki K; Stepien H; Bartos M; Kuzdak K
Endocr Regul; 2001 Mar; 35(1):9-16. PubMed ID: 11308991
[TBL] [Abstract][Full Text] [Related]
11. [Expression of matrix metalloproteinase-2, 9 and it's tissue inhibitor-1, 2 in endometrial carcinoma].
Guo W; Chen G; Zhu C; Wang H
Zhonghua Fu Chan Ke Za Zhi; 2002 Oct; 37(10):604-7. PubMed ID: 12487935
[TBL] [Abstract][Full Text] [Related]
12. Basement membrane remodeling in skeletal muscles of patients with limb ischemia involves regulation of matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases.
Baum O; Ganster M; Baumgartner I; Nieselt K; Djonov V
J Vasc Res; 2007; 44(3):202-13. PubMed ID: 17337906
[TBL] [Abstract][Full Text] [Related]
13. [Expression of matrix metaloproteinase and tissue inhibitors in ovarian tumors].
Cai W; Song JD
Ai Zheng; 2002 Jan; 21(1):91-4. PubMed ID: 12500407
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of matrix metalloproteinase (MMP)-2, MMP-9 and tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 in non-melanoma skin cancer: implications for tumour progression.
O'Grady A; Dunne C; O'Kelly P; Murphy GM; Leader M; Kay E
Histopathology; 2007 Dec; 51(6):793-804. PubMed ID: 18042068
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between expression of MMP-2, MMP-9, TIMP-2, TIMP-1 and metastasis of neuroblastoma].
Cheng Y; Dong Q; Sun LR; Yang CM; Jiang BX
Zhonghua Zhong Liu Za Zhi; 2005 Mar; 27(3):164-6. PubMed ID: 15946567
[TBL] [Abstract][Full Text] [Related]
16. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer.
Iniesta P; Morán A; De Juan C; Gómez A; Hernando F; García-Aranda C; Frías C; Díaz-López A; Rodríguez-Jiménez FJ; Balibrea JL; Benito M
Oncol Rep; 2007 Jan; 17(1):217-23. PubMed ID: 17143501
[TBL] [Abstract][Full Text] [Related]
17. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer.
Morán A; Iniesta P; García-Aranda C; De Juan C; Díaz-López A; Sánchez-Pernaute A; Torres AJ; Díaz-Rubio E; Balibrea JL; Benito M
Oncol Rep; 2005 Jan; 13(1):115-20. PubMed ID: 15583811
[TBL] [Abstract][Full Text] [Related]
18. Plasma MMP-2-TIMP-2 complex levels measured during follow-up predict a risk of relapse in patients with malignant lymphoma.
Pennanen H; Kuittinen O; Turpeenniemi-Hujanen T
Eur J Haematol; 2008 Jan; 80(1):46-54. PubMed ID: 18028436
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinases and their inhibitors in malignant and autoreactive pericardial effusion.
Lamparter S; Schoppet M; Christ M; Pankuweit S; Maisch B
Am J Cardiol; 2005 May; 95(9):1065-9. PubMed ID: 15842972
[TBL] [Abstract][Full Text] [Related]
20. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]